CRRTF (Crescita Therapeutics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRRTF Crescita Therapeutics Inc CRRTF
22 GF Score
Price $0.56
GF Value $0.50
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CRRTF vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Short Interest falls into.


CRRTF
22GF Score
Crescita Therapeutics Inc CRRTF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crescita Therapeutics (CRRTF) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of $0.56 is trading 11.7% above its estimated GF Value™ of $0.50. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for CRRTF:

  • Short Interest:
  • GF Value™: $0.50 vs. price of $0.56 (11.7% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the CRRTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
22GF Score

Get the complete analysis for CRRTF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.50
GF Value